Drug intelligence / Profile preview

CL-994

Development stage: Preclinical
Lead developer: Pfizer
Modality: Small Molecules
Administration: Oral

Overview

CL-994 is a pharmacological inhibitor of histone deacetylases (HDACs). In a mouse model of Myasthenia Gravis, CL-994 has been shown to reduce the production of the inflammatory cytokine IL-6 and autoantibody levels, specifically anti-acetylcholine receptor (AChR) IgG2b. This reduction in inflammation and autoantibodies correlates with milder disease and preservation of muscle AChR. The drug's effects are linked to isoform-specific modulation of HDACs, with both HDAC1 and HDAC2 inhibition contributing to its therapeutic potential.

Targets

HDAC1 (Histone Deacetylase 1)HDAC8 (Histone Deacetylase 8)

Beyond the preview

Go deeper on CL-994.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CL-994.

Explore the full profile